MBIO vs. ARAV, BPTS, AGRX, CYCC, NBY, BPTSY, ARDS, ONCO, VRPX, and CYTO
Should you be buying Mustang Bio stock or one of its competitors? The main competitors of Mustang Bio include Aravive (ARAV), Biophytis (BPTS), Agile Therapeutics (AGRX), Cyclacel Pharmaceuticals (CYCC), NovaBay Pharmaceuticals (NBY), Biophytis (BPTSY), Aridis Pharmaceuticals (ARDS), Onconetix (ONCO), Virpax Pharmaceuticals (VRPX), and Altamira Therapeutics (CYTO). These companies are all part of the "pharmaceutical preparations" industry.
Aravive (NASDAQ:ARAV) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, media sentiment, profitability, earnings and risk.
Aravive has a beta of 2.07, meaning that its share price is 107% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.
Aravive currently has a consensus price target of $13.50, suggesting a potential upside of 33,565.84%. Mustang Bio has a consensus price target of $11.50, suggesting a potential upside of 3,798.31%. Given Mustang Bio's higher possible upside, equities research analysts clearly believe Aravive is more favorable than Mustang Bio.
In the previous week, Mustang Bio had 15 more articles in the media than Aravive. MarketBeat recorded 15 mentions for Mustang Bio and 0 mentions for Aravive. Aravive's average media sentiment score of 0.91 beat Mustang Bio's score of 0.00 indicating that Mustang Bio is being referred to more favorably in the news media.
Mustang Bio has lower revenue, but higher earnings than Aravive. Mustang Bio is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.
35.8% of Aravive shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Comparatively, 2.1% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Mustang Bio has a net margin of 0.00% compared to Mustang Bio's net margin of -569.65%. Mustang Bio's return on equity of 0.00% beat Aravive's return on equity.
Mustang Bio received 65 more outperform votes than Aravive when rated by MarketBeat users. Likewise, 64.26% of users gave Mustang Bio an outperform vote while only 62.28% of users gave Aravive an outperform vote.
Summary
Aravive beats Mustang Bio on 9 of the 17 factors compared between the two stocks.
Get Mustang Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mustang Bio Competitors List
Related Companies and Tools
